$1.6M NIH Grant Awarded for the Development of the Kalm Patch
Huntsville, Alabama--(Newsfile Corp. - October 23, 2024) - Kalm Therapeutics and CFD Research are pleased to announce a SBIR Phase 2 Grant award from the NIH National Center for Complementary and Integrative Health (NCCIH). This nondilutive funding will help propel the Kalm Patch into clinical trials for the treatment of eczema and psoriasis. Safety, efficacy, and manufacturing studies will be conducted per FDA recommendations with this funding. The microbiome balancing potential of the...
2024-10-23 8:00 AM EDT
Innovate Alabama Makes Direct Investment in Kalm Therapeutics
Huntsville, Alabama--(Newsfile Corp. - October 10, 2024) - Kalm Therapeutics is pleased to announce the direct investment from Innovate Alabama through the InvestAL program, made possible by the State Small Business Credit Initiative (SSBCI). This funding requires that the receiving company has raised an equivalent or higher amount of private investment. Kalm is InvestAL's largest and first life science investment to date. These funds will directly contribute to further execution toward our...
2024-10-10 2:48 PM EDT
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief Medical Officer. Dr. Maeda-Chubachi, a board-certified dermatologist will oversee the design and submission of our Phase 1b/2a clinical trial protocol to the FDA."Although many treatments are currently in development, eczema remains a perplexing disease that necessitates diverse therapeutic options. I am excited...
2024-09-16 8:00 AM EDT